MA37762B1 - Composés n-aryltriazole utilisés comme antagonistes de lpar - Google Patents
Composés n-aryltriazole utilisés comme antagonistes de lparInfo
- Publication number
- MA37762B1 MA37762B1 MA37762A MA37762A MA37762B1 MA 37762 B1 MA37762 B1 MA 37762B1 MA 37762 A MA37762 A MA 37762A MA 37762 A MA37762 A MA 37762A MA 37762 B1 MA37762 B1 MA 37762B1
- Authority
- MA
- Morocco
- Prior art keywords
- lpar
- antagonists
- compounds used
- aryltriazole
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
Abstract
L'invention concerne des composés de formule (i) ainsi que des sels pharmaceutiquement acceptables de ceux-ci, les substituants étant ceux qui sont indiqués dans la description. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies et de troubles inflammatoires tels que le fibrose pulmonaire par exemple.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661953P | 2012-06-20 | 2012-06-20 | |
PCT/EP2013/062463 WO2013189865A1 (fr) | 2012-06-20 | 2013-06-17 | Composés n-aryltriazole utilisés comme antagonistes de lpar |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37762A1 MA37762A1 (fr) | 2017-07-31 |
MA37762B1 true MA37762B1 (fr) | 2018-04-30 |
Family
ID=48628669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37762A MA37762B1 (fr) | 2012-06-20 | 2013-06-17 | Composés n-aryltriazole utilisés comme antagonistes de lpar |
Country Status (22)
Country | Link |
---|---|
US (1) | US20150133512A1 (fr) |
EP (1) | EP2864301A1 (fr) |
JP (1) | JP2015520203A (fr) |
KR (1) | KR20150011389A (fr) |
CN (1) | CN104395299A (fr) |
AU (1) | AU2013279513A1 (fr) |
BR (1) | BR112014030674A2 (fr) |
CA (1) | CA2869564A1 (fr) |
CL (1) | CL2014003241A1 (fr) |
CO (1) | CO7131357A2 (fr) |
EA (1) | EA201492281A1 (fr) |
HK (1) | HK1206339A1 (fr) |
IL (1) | IL236087A0 (fr) |
IN (1) | IN2014DN09352A (fr) |
MA (1) | MA37762B1 (fr) |
MX (1) | MX2014014711A (fr) |
PE (1) | PE20142305A1 (fr) |
PH (1) | PH12014502363A1 (fr) |
SG (1) | SG11201407228PA (fr) |
UA (1) | UA110310C2 (fr) |
WO (1) | WO2013189865A1 (fr) |
ZA (1) | ZA201408167B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
BR112015023267B1 (pt) | 2013-03-15 | 2023-01-31 | Epigen Biosciences, Inc | Composto, e medicamento para tratar um indivíduo com doença ou condição lisofosfatídica dependente de ácido |
UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
KR102433588B1 (ko) | 2014-06-27 | 2022-08-19 | 우베 가부시키가이샤 | 할로겐 치환 헤테로환 화합물의 염 |
WO2017055316A1 (fr) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Composés azole à substitution amido |
WO2017055313A1 (fr) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Composés azole amido-substitués |
AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
WO2018078005A1 (fr) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Dérivés d'azaspiro à substitution amido en tant qu'inhibiteurs de tankyrase |
WO2018078009A1 (fr) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Dérivés de cyclohexane à substitution amido |
WO2018087126A1 (fr) | 2016-11-09 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dérivés de cyclohexane à substitution amido en tant qu'inhibiteurs de tankyrase |
CN107827829A (zh) * | 2017-11-07 | 2018-03-23 | 大连理工大学 | 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法 |
CN107721984A (zh) * | 2017-11-07 | 2018-02-23 | 大连理工大学 | 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法 |
EA202091500A1 (ru) | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa |
WO2019126098A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Acides carbamoyle cyclohexyliques à liaison o pyrazole utilisés en tant qu'antagonistes de lpa |
CN111479807A (zh) | 2017-12-19 | 2020-07-31 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑吖嗪 |
JP7299892B2 (ja) | 2017-12-19 | 2023-06-28 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン |
CN112074515A (zh) | 2017-12-19 | 2020-12-11 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
MX2020005818A (es) | 2017-12-19 | 2020-08-20 | Bristol Myers Squibb Co | Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). |
ES2925626T3 (es) | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
WO2019126093A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa |
WO2019126099A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Acides carbamoyle cyclohexyliques à liaison n isoxazole utilisés en tant qu'antagonistes de lpa |
CN112041029A (zh) | 2017-12-19 | 2020-12-04 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸吡唑唑类 |
CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
EP4058144A1 (fr) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Pyridylsulfonamides de carbamate de triazole utilisées en tant qu'antagonistes du récepteur de lpa et leurs utilisations |
KR20230019880A (ko) | 2020-06-03 | 2023-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
TW202344504A (zh) | 2020-06-03 | 2023-11-16 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
CN115745848A (zh) * | 2022-12-07 | 2023-03-07 | 上海优合生物科技有限公司 | 一种氨基胍的加工合成工艺 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011159550A2 (fr) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Antagoniste du récepteur de l'acide lysophosphatidique et ses utilisations |
WO2011159633A1 (fr) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Formulations inhalables d'antagonistes de récepteur d'acide lysophosphatidique |
BR112013014019A2 (pt) * | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | antagonistas do receptor do ácido lisofosfatídico e seus usos |
WO2012138648A1 (fr) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions et procédés pour la modulation de récepteurs au lpa |
AU2012296662A1 (en) * | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
IN2014DN09348A (fr) * | 2012-06-20 | 2015-07-17 | Hoffmann La Roche |
-
2013
- 2013-06-17 UA UAA201500426A patent/UA110310C2/uk unknown
- 2013-06-17 EP EP13729332.0A patent/EP2864301A1/fr not_active Withdrawn
- 2013-06-17 IN IN9352DEN2014 patent/IN2014DN09352A/en unknown
- 2013-06-17 US US14/403,261 patent/US20150133512A1/en not_active Abandoned
- 2013-06-17 CA CA2869564A patent/CA2869564A1/fr not_active Abandoned
- 2013-06-17 SG SG11201407228PA patent/SG11201407228PA/en unknown
- 2013-06-17 WO PCT/EP2013/062463 patent/WO2013189865A1/fr active Application Filing
- 2013-06-17 KR KR1020147035551A patent/KR20150011389A/ko not_active Application Discontinuation
- 2013-06-17 MX MX2014014711A patent/MX2014014711A/es unknown
- 2013-06-17 JP JP2015517705A patent/JP2015520203A/ja active Pending
- 2013-06-17 AU AU2013279513A patent/AU2013279513A1/en not_active Abandoned
- 2013-06-17 EA EA201492281A patent/EA201492281A1/ru unknown
- 2013-06-17 BR BR112014030674A patent/BR112014030674A2/pt not_active Application Discontinuation
- 2013-06-17 CN CN201380031806.0A patent/CN104395299A/zh active Pending
- 2013-06-17 MA MA37762A patent/MA37762B1/fr unknown
- 2013-06-17 PE PE2014002213A patent/PE20142305A1/es not_active Application Discontinuation
-
2014
- 2014-10-22 PH PH12014502363A patent/PH12014502363A1/en unknown
- 2014-11-07 ZA ZA2014/08167A patent/ZA201408167B/en unknown
- 2014-11-20 CO CO14255124A patent/CO7131357A2/es unknown
- 2014-11-28 CL CL2014003241A patent/CL2014003241A1/es unknown
- 2014-12-04 IL IL236087A patent/IL236087A0/en unknown
-
2015
- 2015-07-21 HK HK15106924.1A patent/HK1206339A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PE20142305A1 (es) | 2015-01-16 |
EA201492281A1 (ru) | 2015-04-30 |
CL2014003241A1 (es) | 2015-03-20 |
AU2013279513A1 (en) | 2014-10-16 |
CO7131357A2 (es) | 2014-12-01 |
JP2015520203A (ja) | 2015-07-16 |
MX2014014711A (es) | 2015-03-04 |
PH12014502363A1 (en) | 2015-01-12 |
IN2014DN09352A (fr) | 2015-07-17 |
US20150133512A1 (en) | 2015-05-14 |
UA110310C2 (uk) | 2015-12-10 |
KR20150011389A (ko) | 2015-01-30 |
WO2013189865A1 (fr) | 2013-12-27 |
HK1206339A1 (en) | 2016-01-08 |
BR112014030674A2 (pt) | 2017-06-27 |
SG11201407228PA (en) | 2014-12-30 |
MA37762A1 (fr) | 2017-07-31 |
IL236087A0 (en) | 2015-02-01 |
CA2869564A1 (fr) | 2013-12-27 |
CN104395299A (zh) | 2015-03-04 |
ZA201408167B (en) | 2015-12-23 |
EP2864301A1 (fr) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
MA35285B1 (fr) | Indazoles | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA35576B1 (fr) | Nouveaux composés | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
MA54386B1 (fr) | Modulateurs de trex1 | |
MA35184B1 (fr) | Antagonistes de trpv4 | |
MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
MA38207A2 (fr) | Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées | |
MA45867B1 (fr) | Modulateurs du récepteur des oestrogènes |